GI endoscopy · Surgical and interventional solutions · Single-use therapy devices
Olympus
Olympus is a Japanese medical-device company supplying gastrointestinal endoscopy and endotherapy plus urology, respiratory and surgical solutions. FY2027 Q1 revenue rose 16.4% to JPY240.4 billion, with Gastrointestinal Solutions contributing 70%.
Business categories Medical Devices & Supplies · Biopharma & Life Sciences · primary
7733.T Updated Oct 13, 2026 4 AI consumers· 4 recurring
Per the valuechain.wiki graph, Olympus is directly linked to 2 companies (2 supply, 0 revenue relationships) and reaches 5 companies within two hops; the links are backed by 9 dated sources, 2 of them primary filings (as of 2026-10-13).
Financials & Segments
- Total revenue · FY2027 Q1 consolidated revenue JPY240.4 billion (+16.4%)
- Customer concentration · No customer-level revenue concentration disclosed; hospital and care-provider demand in North America and Europe is central
- Segments · Gastrointestinal Solutions · Surgical & Interventional Solutions
Revenue from
- Gastrointestinal Solutions customers (hospitals and care providers) High confidence· Amount 168,448 JPY_million · FY2027 Q1 · Gastrointestinal Solutions revenue
Olympus supplies endoscopy, endotherapy and services to hospitals and care providers. FY2027 Q1 Gastrointestinal Solutions revenue rose 21.2% to JPY168.448 billion.Confirms EN Olympus Corporation Published Aug 7, 2026: Consolidated Financial Results for the Three Months of FY2027Mentions KO Dailypharm Published Jul 8, 2026: Olympus Korea revenue recovers to KRW 230 billion as profitability and therapy lineup strengthenMentions KO Samsung Securities Published Sep 10, 2024: Medical devices: Korean gastrointestinal devices recognized overseas - Surgical & Interventional Solutions customers (hospitals and care providers) High confidence· Amount 71,923 JPY_million · FY2027 Q1 · Surgical & Interventional Solutions revenue
Olympus supplies urology, respiratory and surgical-endoscopy products to hospitals and care providers. FY2027 Q1 division revenue rose 6.7% to JPY71.923 billion.Confirms EN Olympus Corporation Published Aug 7, 2026: Consolidated Financial Results for the Three Months of FY2027Mentions KO Samsung Securities Published Sep 10, 2024: Medical devices: Korean gastrointestinal devices recognized overseas
Pays to
- Other component and material suppliers (undisclosed) High confidence· Amount 83,573 JPY_million · FY2027 Q1 · consolidated cost of sales, including disclosed relationships such as DuPont and Canon
The filing does not disclose purchases by individual supplier. FY2027 Q1 consolidated cost of sales was JPY83.573 billion, or 34.8% of revenue.Confirms EN Olympus Corporation Published Aug 7, 2026: Consolidated Financial Results for the Three Months of FY2027 - DuPont High confidence· Count 100 device_categories · from 2026 · single-use device categories adopting Tyvek with Renewable Attribution
From 2026, Olympus is adopting DuPont Tyvek in sterile packaging for more than 100 single-use endotherapy device categories. Contract value is undisclosed.Confirms KO Mordor Intelligence Published Aug 1, 2026: Sterilization Pouches Market Size, Share and Growth Trends to 2031Confirms EN Olympus Corporation Published Sep 30, 2025: Olympus Commits to Advancing Sustainable Packaging Enabled by DuPont Tyvek with Renewable Attribution - Canon High confidence
Canon Medical develops and manufactures the Aplio i800 EUS ultrasound system, while Olympus sells and markets it with Olympus ultrasound endoscopes. Transaction value is undisclosed.Confirms KO Medical Times Published Apr 8, 2026: Canon and Olympus jointly target the endoscopic ultrasound marketConfirms EN Olympus Corporation Published Jan 15, 2024: Canon Medical Systems and Olympus Announce Business Alliance regarding Endoscopic Ultrasound Systems
Investments
- BioProtect High confidence· Amount 270 USD_million · 2026 · cost to acquire 100% of BioProtect, including milestone payment
Olympus acquired 100% of BioProtect for $270 million in June 2026, adding biodegradable rectal spacers for prostate-cancer care.Confirms EN Olympus Corporation Published Jun 2, 2026: Notice Regarding Completion of Acquisition of BioProtect Ltd.
Value-chain ripple (2 tiers)
Following node-to-node links up to 2 tiers; each firm is shown once, at its nearest tier.
| Company | Chain | '21 | '22 | '23 | '24 | '25 | YTD |
|---|---|---|---|---|---|---|---|
| Olympus | node | +35.5 | -4.1 | -8.8 | +8.5 | -21.4 | +14.2 |
| DuPont | benef1 | +15.4 | -13.4 | +14.4 | +1 | +28.7 | +10.5 |
| Canon | benef1 | +22.5 | +11.1 | +46.4 | +27 | -3.2 | +2.4 |
| Qnity Electronics | benef2 | · | · | · | · | · | +55.3 |
| International Flavors & Fragrances | benef2 | +41.5 | -28.3 | -19.5 | +6.3 | -18.4 | +27.5 |
| Dai Nippon Printing | benef2 | +56.5 | +13.9 | +42.6 | +8.5 | +22.5 | +7.4 |
YTD as of 2026-09-04 · source: Yahoo Finance
Olympus shares fell 21.4% in 2025 and rebounded 14.2% in 2026. Medical-packaging supplier DuPont gained 28.7% in 2025 and 10.5% in 2026, while ultrasound-system partner Canon fell 3.2% in 2025 and rose only 2.4% in 2026. Olympus FY2027 Q1 revenue increased 16.4%, led by 21.2% growth in Gastrointestinal Solutions, but the demand recovery did not reach supplier equities at the same speed. Olympus sits close to Fujifilm Holdings, up 13.6% in 2026, in a medical-device rebound. Canon is the lagging listed link. DuPont is driven more by the Qnity separation and its mixed industrial portfolio than by packaging demand alone. Regulatory and quality actions plus U.S. tariffs are exceptions that can interrupt propagation.
Analysis generated from returns as of 2026-09-04← All companiesMarkdown · JSON · Customers · Suppliers · Ripple